MENU
+Compare
CRVS
Stock ticker: NASDAQ
AS OF
Nov 20, 04:59 PM (EDT)
Price
$8.52
Change
-$0.38 (-4.27%)
Capitalization
635.54M

CRVS Corvus Pharmaceuticals Forecast, Technical & Fundamental Analysis

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function... Show more

CRVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CRVS with price predictions
Nov 19, 2025

Aroon Indicator for CRVS shows an upward move is likely

CRVS's Aroon Indicator triggered a bullish signal on November 19, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 161 similar instances where the Aroon Indicator showed a similar pattern. In of the 161 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 30, 2025. You may want to consider a long position or call options on CRVS as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CRVS just turned positive on November 12, 2025. Looking at past instances where CRVS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in of 239 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CRVS moved out of overbought territory on November 19, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRVS broke above its upper Bollinger Band on November 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.857) is normal, around the industry mean (27.606). P/E Ratio (0.000) is within average values for comparable stocks, (52.154). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.053). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.190).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CRVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CRVS is expected to report earnings to fall 2.75% to -11 cents per share on March 05

Corvus Pharmaceuticals CRVS Stock Earnings Reports
Q4'25
Est.
$-0.12
Q3'25
Beat
by $0.01
Q2'25
Beat
by $0.03
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.06
The last earnings report on November 04 showed earnings per share of -11 cents, beating the estimate of -12 cents. With 677.71K shares outstanding, the current market capitalization sits at 635.54M.
A.I. Advisor
published General Information

General Information

a provider of anticancer immuno-oncology drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
863 Mitten Road
Phone
+1 650 900-4520
Employees
28
Web
https://www.corvuspharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RPMIX9.330.03
+0.32%
Royce Small-Cap Fund Instl
IJMSX13.81N/A
N/A
VY® JPMorgan Mid Cap Value S
ESEAX32.06N/A
N/A
Eaton Vance Atlanta Capital Sel Eq A
SESGX25.39N/A
N/A
Sit ESG Growth S
JGAVX88.93-0.06
-0.07%
JPMorgan US Value R3

CRVS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-1.98%
SYRE - CRVS
44%
Loosely correlated
+0.83%
IPSC - CRVS
43%
Loosely correlated
+4.82%
UPB - CRVS
41%
Loosely correlated
-2.62%
RZLT - CRVS
40%
Loosely correlated
N/A
AMLX - CRVS
37%
Loosely correlated
+2.80%
More